Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NeoRx gets recommendation for Verluma:

This article was originally published in Clinica

Executive Summary

The US FDA Oncologic Drugs Advisory Committee has recommended approval for Verluma, NeoRx' small cell lung cancer imaging agent. Verluma is an antibody-technetium conjugate. Cancer is staged by whole body gamma scan 14 to 17 hours after injection. A PLA was filed in March 1994 by the manufacturer, Boehringer Ingelheim, which also holds non-North American marketing rights, DuPont Merck holds exclusive marketing rights for North America. Verluma will be manufactured in Germany by Boehringer Ingelheim subsidiary Dr Karl Thomae. Between 40 and 45,000 cases of small cell lung cancer are diagnosed every year in the US. About 70% are classed as extensive.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts